Insights from 2023 ESMO Asia Annual Meeting
Oncogene-Driven NSCLC: RET, NTRK, and ROS1
On November 15, 2023, the FDA approved repotrectinib (brand name Augtyro) for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Login to view comments.
Click here to Login
